Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)

Not Applicable

• Conditions: Neuroendocrine Tumors; Peptide Receptor Radionuclide Therapy (PRRT)
• Interventions: Radiation: Lutetium-177 (177Lu)-DOTATOC; Radiation: Yttrium-90 (90Y)-DOTATOC; Radiation: 177Lu-DOTATOC + 90Y-DOTATOC; Radiation: Re-treatment 177Lu-DOTATOC; Radiation: Re-treatment 90Y-DOTATOC

• Registration Number: NCT04790708
• Lead Sponsor: University Hospital of Ferrara

Brief Summary

The rationale behind the purpose of this study lays on:

* the evidence that PRRT could represent a valuable treatment for the majority of patients with neuroendocrine tumor (NET) in disease progression, operated or inoperable, presenting lesions expressing somatostatin receptors and for which standard treatments are not already available;

* the current impossibility of acquiring on the market radiolabelled analogues of somatostatin used for PRRT with marketing authorisation;

* the need to collect a larger case history than in previous studies;

* the need to stratify the various histotypes based on the response obtained;

* the need to define new treatment schemes that guarantee the maximum efficacy and the lowest possible toxicity - with low cumulative (and per cycle) activities radiopharmaceutical and according to the concept of dose hyperfractionation - with a view to an optimal balance between risk and benefit.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-07-02
• Status Verified: 2021-03
• Study First Submitted: 2021-03-02
• Study First Submitted QC: 2021-03-05
• Last Update Submitted: 2021-03-05
• Study First Posted: 2021-03-10
• Last Update Posted: 2021-03-10
• Primary Completion: 2023-06-30
• Study Completion: 2023-06-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

• 1. Age ≥18 years, of both sexes, of any ethnicity;
• 2. Cyto-histological and immunohistochemical diagnosis of NET;
• 3. Evaluation of the cell proliferation index by studying Ki-67 and / or E3 ubiquitin-protein ligase (MIB-1).
• 4. Illness measurable according to RECIST 1.1 criteria by imaging conventional (CT with contrast medium or MRI with contrast medium) not earlier than two months with respect to enrollment;
• 5. Elevated expression of somatostatin receptors documented by PET-CT with 68Ga-DOTATOC in the target lesion (s). It is defined as "high expression of somatostatin receptors "a ratio of Maximum standardized uptake value (SUVmax) lesion / Mean standardized uptake value (SUVmean) muscle ≥ 4: 1 calculated with semi-quantitative analysis on examination PET-CT with 68Ga-DOTATOC;
• 6. Dosage of Chromogranin A (and any other specific markers) not prior to two months of enrollment;
• 7. Evaluation of glucose metabolism in the target lesion (s) by PET-CT with 18F-FDG;
• 8. Preserved haematological, hepatic and renal parameters, in particular: white blood cells ≥2500 / μL; platelets ≥ 90000 / μL; hemoglobin ≥ 9 gr / dL; creatinine ≤ 2 mg / dL; bilirubin ≤ 2.5 mg / dL
• 9. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
• 10. Life expectancy ≥ 6 months;
• 11. Stable or progressive disease, at any stage, both in operated patients that inoperable;
• 12. Absence of standard treatments already documented and of equal effectiveness;
• 13. Absence of surgical, chemotherapy and / or radiotherapy treatments for at least 30 days. On the other hand, patients in therapy with somatostatin analogues or biologics, such as mechanistic target of rapamycin (m-TOR) inhibitors;
• 14. Voluntary participation in the study by signing the consent form informed, after reading and complete understanding of the information notes.

Exclusion Criteria

• 1. Lack of the requirements listed above;
• 2. State of pregnancy;
• 3. Breastfeeding and relative refusal to suspend breastfeeding;
• 4. Participation in another therapeutic experimental clinical protocol in the four weeks prior to the PRRT;
• 5. Bone marrow invasion of disease> 25% confirmed;
• 6. Previous extensive radiotherapy treatments.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Midgut NETs	Re-treatment 177Lu-DOTATOC	75 patients affected by non-functional and functional NETs arising from: stomach, duodenum, jejunum, ileum, colon and rectum.
Pancreatic NETs	Lutetium-177 (177Lu)-DOTATOC	75 patients affected by non-functional and functional NETs arising from Pancreas.
Sympathetic-Adrenergic axis NEts	Lutetium-177 (177Lu)-DOTATOC	25 patients affected by non-functional and functional: Pheochromocytoma, Paraganglioma and Neuroblastoma
Other Nets	177Lu-DOTATOC + 90Y-DOTATOC	25 patients affected by non-functional and functional NETs arising from Skin, Thyroid (medullary thyroid and anaplastic cancer) and Parathyroids.
Other Nets	Re-treatment 177Lu-DOTATOC	25 patients affected by non-functional and functional NETs arising from Skin, Thyroid (medullary thyroid and anaplastic cancer) and Parathyroids.
Midgut NETs	Yttrium-90 (90Y)-DOTATOC	75 patients affected by non-functional and functional NETs arising from: stomach, duodenum, jejunum, ileum, colon and rectum.
Midgut NETs	Lutetium-177 (177Lu)-DOTATOC	75 patients affected by non-functional and functional NETs arising from: stomach, duodenum, jejunum, ileum, colon and rectum.
Pancreatic NETs	Yttrium-90 (90Y)-DOTATOC	75 patients affected by non-functional and functional NETs arising from Pancreas.
Sympathetic-Adrenergic axis NEts	177Lu-DOTATOC + 90Y-DOTATOC	25 patients affected by non-functional and functional: Pheochromocytoma, Paraganglioma and Neuroblastoma
Other Nets	Lutetium-177 (177Lu)-DOTATOC	25 patients affected by non-functional and functional NETs arising from Skin, Thyroid (medullary thyroid and anaplastic cancer) and Parathyroids.
Cancers of Unknown Primary Origin (CUP) NETs	Re-treatment 177Lu-DOTATOC	25 patients affected by non-functional and functional unknown primary NETs
Cancers of Unknown Primary Origin (CUP) NETs	Re-treatment 90Y-DOTATOC	25 patients affected by non-functional and functional unknown primary NETs
Midgut NETs	Re-treatment 90Y-DOTATOC	75 patients affected by non-functional and functional NETs arising from: stomach, duodenum, jejunum, ileum, colon and rectum.
Bronchial NETs	Lutetium-177 (177Lu)-DOTATOC	25 patients affected by non-functional and functional Bronchial NETs.
Bronchial NETs	Yttrium-90 (90Y)-DOTATOC	25 patients affected by non-functional and functional Bronchial NETs.
Bronchial NETs	Re-treatment 90Y-DOTATOC	25 patients affected by non-functional and functional Bronchial NETs.
Sympathetic-Adrenergic axis NEts	Re-treatment 90Y-DOTATOC	25 patients affected by non-functional and functional: Pheochromocytoma, Paraganglioma and Neuroblastoma
Other Nets	Yttrium-90 (90Y)-DOTATOC	25 patients affected by non-functional and functional NETs arising from Skin, Thyroid (medullary thyroid and anaplastic cancer) and Parathyroids.
Midgut NETs	177Lu-DOTATOC + 90Y-DOTATOC	75 patients affected by non-functional and functional NETs arising from: stomach, duodenum, jejunum, ileum, colon and rectum.
Pancreatic NETs	177Lu-DOTATOC + 90Y-DOTATOC	75 patients affected by non-functional and functional NETs arising from Pancreas.
Cancers of Unknown Primary Origin (CUP) NETs	Yttrium-90 (90Y)-DOTATOC	25 patients affected by non-functional and functional unknown primary NETs
Pancreatic NETs	Re-treatment 177Lu-DOTATOC	75 patients affected by non-functional and functional NETs arising from Pancreas.
Pancreatic NETs	Re-treatment 90Y-DOTATOC	75 patients affected by non-functional and functional NETs arising from Pancreas.
Bronchial NETs	177Lu-DOTATOC + 90Y-DOTATOC	25 patients affected by non-functional and functional Bronchial NETs.
Bronchial NETs	Re-treatment 177Lu-DOTATOC	25 patients affected by non-functional and functional Bronchial NETs.
Sympathetic-Adrenergic axis NEts	Yttrium-90 (90Y)-DOTATOC	25 patients affected by non-functional and functional: Pheochromocytoma, Paraganglioma and Neuroblastoma
Sympathetic-Adrenergic axis NEts	Re-treatment 177Lu-DOTATOC	25 patients affected by non-functional and functional: Pheochromocytoma, Paraganglioma and Neuroblastoma
Cancers of Unknown Primary Origin (CUP) NETs	177Lu-DOTATOC + 90Y-DOTATOC	25 patients affected by non-functional and functional unknown primary NETs
Other Nets	Re-treatment 90Y-DOTATOC	25 patients affected by non-functional and functional NETs arising from Skin, Thyroid (medullary thyroid and anaplastic cancer) and Parathyroids.
Cancers of Unknown Primary Origin (CUP) NETs	Lutetium-177 (177Lu)-DOTATOC	25 patients affected by non-functional and functional unknown primary NETs

Primary Outcome Measures

Name	Time	Method
Disease Control Rate	12 months	Post-treatment evaluation will be performed with: * a clinical examination; * a comparative morphological re-evaluation, using version 1.1 of Response evaluation criteria in solid tumors (RECIST criteria) on Computed Tomography (CT); * a comparative functional re-evaluation, performed both on 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission computed tomography (PET/CT) and Gallium-68 (68Ga)-DOTATOC PET/CT using visual and semi-quantitative parameters (such as SUVmax).; Based on all these parameters, Disease Control Rate will be labelled as: Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progression Disease (PD).

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival	6 months	Progression free survival is defined as the time intercurrent from treatment start to the date of first observation of documented disease progression or death due to any cause.
Evaluation of PRRT Safety	6 months	The evaluation of Treatment-Emergent Adverse Events, defined as any G3/G4 toxicity. The evaluation will be performed during every treatment cycle and after 12, 18, 24, 30, 36 and 42 months after the last treatment cycle and will be based on version 4.0 of Common Terminology Criteria for Adverse Events (CTC-AE) toxicity criteria.
Evaluation of Quality of Life	6 months	Quality of Life (QoL) will be evaluated with quality of life questionnaire, version 3 (QLQ-C30) by European Organisation for Research and Treatment of Cancer (EORTC). The questionnaire includes five functional scales, three symptom scales, a global health status / QoL scale, and six single items.; All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.
Overall Survival	6 months	Overall survival is defined as the time intercurrent from treatment start to the date of death due to any cause, or the date of last contact.

Trial Locations

Locations (1)

University Hospital of Ferrara; 🇮🇹 Ferrara, Italy